Product logins

Find logins to all Clarivate products below.


Pemphigus Vulgaris – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of pemphigus vulgaris comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of pemphigus vulgaris for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s pemphigus vulgaris forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of pemphigus vulgaris and the number of new diagnoses of pemphigus vulgaris?
  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of pemphigus vulgaris and the number of new diagnoses of pemphigus vulgaris?
  • How will improvements in survival change the number of people living with a diagnosis of pemphigus vulgaris?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of pemphigus vulgaris over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following pemphigus vulgaris subpopulations:

  • Diagnosed incident cases
  • Diagnosed prevalent cases
  • Diagnosed incident cases by severity

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Insomnia – Current Treatment – Current Treatment: Physician Insights – Insomnia (EU5)
Insomnia is a common sleep disorder characterized by difficulty initiating or maintaining sleep, leading to impaired daytime functioning. Its management is highly personalized, with clinicians…
Report
Parkinson’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Several new brands have recently entered the competitive Parkinson’s disease (PD) therapy market, including AbbVie’s Vyalev / Produodopa / Scyova (foslevodopa / foscarbidopa subcutaneous pump…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…